Payment overview · 2025
General Payments
$476.58
17 reported records · 9 companies
Healthcare provider profile · identity verified
James Robinson, MD
Allopathic & Osteopathic Physicians|Family Medicine · SOUTHSIDE, AL · NPI 1649237835
Verified facts
What the public records show
CMS Open Payments records show James Robinson, MD received $476.58 in general payments during 2025 across 17 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 30.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 246 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $146.06 | 30.6% | 7 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $136.16 | 28.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $65.82 | 13.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.56 | 8.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.20 | 4.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.71 | 4.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.68 | 3.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.81 | 3.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.58 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $476.58 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $146.06 | 7 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $136.16 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $65.82 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.20 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.20 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $21.85 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.71 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 246 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 32 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 79 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
79 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
79 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
246 | 49 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 894 | 238 |
| Amlodipine Besylate | Amlodipine Besylate | 672 | 199 |
| Losartan Potassium | Losartan Potassium | 595 | 175 |
| Atorvastatin Calcium | Atorvastatin Calcium | 522 | 148 |
| Omeprazole | Omeprazole | 451 | 128 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 396 | 83 |
| Meloxicam | Meloxicam | 374 | 114 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 370 | 117 |
| Duloxetine Hcl | Duloxetine Hcl | 365 | 89 |
| Glimepiride | Glimepiride | 341 | 100 |
| Pantoprazole Sodium | Pantoprazole Sodium | 340 | 100 |
| Hydrochlorothiazide | Hydrochlorothiazide | 337 | 97 |
| Metoprolol Succinate | Metoprolol Succinate | 323 | 93 |
| Simvastatin | Simvastatin | 319 | 93 |
| Potassium Chloride | Potassium Chloride | 311 | 94 |
| Alprazolam | Alprazolam | 310 | 57 |
| Carvedilol | Carvedilol | 307 | 88 |
| Metformin Hcl | Metformin Hcl | 306 | 87 |
| Montelukast Sodium | Montelukast Sodium | 299 | 87 |
| Famotidine | Famotidine | 297 | 87 |
| Gabapentin | Gabapentin | 296 | 76 |
| Lisinopril | Lisinopril | 289 | 88 |
| Pravastatin Sodium | Pravastatin Sodium | 288 | 79 |
| Citalopram Hbr | Citalopram Hydrobromide | 275 | 82 |
| Clonazepam | Clonazepam | 269 | 62 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 269 | 78 |
| Escitalopram Oxalate | Escitalopram Oxalate | 266 | 71 |
| Eliquis | Apixaban | 246 | 49 |
| Lorazepam | Lorazepam | 237 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 235 | 71 |
| Furosemide | Furosemide | 226 | 79 |
| Zolpidem Tartrate | Zolpidem Tartrate | 213 | 53 |
| Tramadol Hcl | Tramadol Hcl | 207 | 55 |
| Trazodone Hcl | Trazodone Hcl | 207 | 56 |
| Azithromycin | Azithromycin | 185 | 154 |
| Temazepam | Temazepam | 170 | 31 |
| Pregabalin | Pregabalin | 164 | 33 |
| Donepezil Hcl | Donepezil Hcl | 159 | 51 |
| Sertraline Hcl | Sertraline Hcl | 150 | 39 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 148 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 147 | 43 |
| Januvia | Sitagliptin Phosphate | 142 | 29 |
| Cefdinir | Cefdinir | 139 | 112 |
| Valsartan | Valsartan | 136 | 37 |
| Ozempic | Semaglutide | 134 | 21 |
| Allopurinol | Allopurinol | 125 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 114 | 44 |
| Ramipril | Ramipril | 109 | 32 |
| Methylprednisolone | Methylprednisolone | 108 | 90 |
| Ondansetron Hcl | Ondansetron Hcl | 107 | 41 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 33 |
| Ibandronate Sodium | Ibandronate Sodium | 102 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 100 | 75 |
| Pioglitazone Hcl | Pioglitazone Hcl | 99 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 92 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 90 | 24 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 89 | 63 |
| Fenofibrate | Fenofibrate | 87 | 24 |
| Spironolactone | Spironolactone | 87 | 27 |
| Methocarbamol | Methocarbamol | 84 | 44 |
| Diclofenac Sodium | Diclofenac Sodium | 82 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 82 | 24 |
| Mounjaro | Tirzepatide | 79 | 16 |
| Trulicity | Dulaglutide | 79 | 11 |
| Celecoxib | Celecoxib | 74 | 26 |
| Farxiga | Dapagliflozin Propanediol | 71 | 13 |
| Novolog Flexpen | Insulin Aspart | 70 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 70 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 23 |
| Aripiprazole | Aripiprazole | 66 | 15 |
| Bupropion Xl | Bupropion Hcl | 65 | 16 |
| Atenolol | Atenolol | 63 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 63 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 25 |
| Xarelto | Rivaroxaban | 63 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | 15 |
| Fluconazole | Fluconazole | 58 | 37 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 17 |
| Megestrol Acetate | Megestrol Acetate | 57 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 57 | 16 |
| Dutasteride | Dutasteride | 56 | 17 |
| Ezetimibe | Ezetimibe | 55 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 54 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 54 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 14 |
| Clonidine Hcl | Clonidine Hcl | 53 | 13 |
| Prednisone | Prednisone | 53 | 20 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 51 | 16 |
| Warfarin Sodium | Warfarin Sodium | 51 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 48 | 17 |
| Lovastatin | Lovastatin | 46 | 12 |
| Valacyclovir | Valacyclovir Hcl | 44 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | 11 |
| Metformin Hcl Er | Metformin Hcl | 42 | 13 |
| Rizatriptan | Rizatriptan Benzoate | 42 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 42 | 12 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Estradiol | Estradiol | 41 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 40 | 27 |
| Meclizine Hcl | Meclizine Hcl | 38 | 15 |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Levofloxacin | Levofloxacin | 37 | 31 |
| Nystatin | Nystatin | 36 | 22 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | 14 |
| Memantine Hcl | Memantine Hcl | 35 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 34 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 34 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 27 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | 12 |
| Primidone | Primidone | 33 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 33 | suppressed |
| Jardiance | Empagliflozin | 32 | 12 |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Glipizide Er | Glipizide | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 27 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Fentanyl | Fentanyl | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Klor-Con M10 | Potassium Chloride | 26 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | 12 |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | 12 |
| Finasteride | Finasteride | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 15 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Testosterone | Testosterone | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Ofloxacin | Ofloxacin | 15 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Etodolac | Etodolac | 14 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Budesonide Er | Budesonide | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 11 |
| Clindamycin Phosphate | Clindamycin Phosphate | 12 | suppressed |
| Depakote Sprinkle | Divalproex Sodium | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $476.58 · 17 records | Bayer Healthcare Pharmaceuticals Inc. | CAPLYTA, Cologuard Collection Kit, ELIQUIS, INSPIRE, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, The Cologuard Plus Collection Kit, VOQUEZNA, Veozah, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error